The involvement of LINC00115 in mediating CRC cell proliferation and migration via modulating the PI3K/AKT/mTOR pathway justifies the idea that anti-LINC00115 compounds or agents consequently targeting the PI3K/AKT/mTOR pathway might serve as novel therapeutic strategies for the CRC treatment. Here, MTOR is linked to colorectal carcinoma.